FOLD241220C5000
- 0.00
- 0.000.00%
Amicus Therapeutics Newsroom
BioNJ Unveils "Time Off for Clinical Trials" Initiative
HALO Vs. FOLD: Which Stock Should Value Investors Buy Now?
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Announces Target Price $17
When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable?
J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating
A Quick Look at Today's Ratings for Amicus Therapeutics(FOLD.US), With a Forecast Between $15 to $21
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Amicus Therapeutics Is Maintained at Buy by Guggenheim
Cantor Fitzgerald Maintains Overweight on Amicus Therapeutics, Raises Price Target to $21
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights
A Quick Look at Today's Ratings for Amicus Therapeutics(FOLD.US), With a Forecast Between $15 to $20
Express News | Amicus Therapeutics Inc : Guggenheim Raises Target Price to $15 From $13
Amicus Therapeutics Analyst Ratings
Earnings Call: Amicus Therapeutics Reports Robust Q3 Growth, Raises Guidance
Amicus Therapeutics | 10-Q: Q3 2024 Earnings Report
Amicus Therapeutics: Strong Financial Performance and Growth Prospects Justify Buy Rating
Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript Summary
Amicus Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Its FY24 Revenue Growth Guidance.